The Rise of Weight Loss Drugs and the Hidden Barriers
For many Brits struggling to lose weight, drugs like Mounjaro and Wegovy have been hailed as game-changers — helping them shed pounds at a speed previously only possible with surgery. However, despite the growing demand for these jabs, some individuals are finding they cannot access the treatment, even if they are willing to pay privately or meet the BMI criteria on paper.
According to a digital healthcare platform, thousands of Brits are being turned away for GLP-1 jabs due to hidden health reasons. There are a whole host of conditions that can make these drugs unsuitable — or even dangerous — for patients, from digestive disorders to mental health issues. Experts are urging people to understand these eligibility rules before pinning their hopes on a prescription.
BMI Eligibility Criteria
One of the most common reasons people are turned away is because they don’t meet the strict BMI requirements needed to qualify for treatment. Dr Kathryn Basford at Asda Online Doctor explains that GLP-1 medications are “designed to treat obesity as a medical condition” and “not intended for cosmetic weight loss alone.” As such, the drugs are usually only prescribed to people who meet specific BMI thresholds, sometimes alongside additional weight-related health conditions.
BMI Criteria for a Mounjaro or Wegovy Prescription
- Mounjaro: Currently, patients need a BMI of at least 35 to 39.9, as well as four or more weight-related health conditions to access this GLP-1 drug on the NHS. From next year, however, the requirement changes to a 40+ BMI with three or more health conditions.
- Wegovy: To be prescribed Wegovy, the other medication of this type approved on the NHS for weight loss purposes, a BMI of over 35, as well as at least one weight-related comorbidity (such as type 2 diabetes, hypertension or obstructive sleep apnoea) is required.
When it comes to private prescriptions for either jab, you typically need a BMI of 30+, or between 27 and 29.9 alongside a weight-related health issue. In both cases, however, doctors can refuse a prescription if there are indications the treatment may be unsafe or ineffective.
Other Health Conditions That May Prevent Access
There are several other health conditions that could render the medications unsuitable:
- Pancreatitis: GLP-1 medications have been linked to inflammation of the pancreas, meaning anyone with a history of pancreatitis may be advised not to take them due to the “potential risk of recurrence.”
- Digestive or gastrointestinal conditions: These medications slow digestion and influence appetite, so people living with conditions such as gastroparesis, severe acid reflux, inflammatory bowel disease, or other significant digestive disorders may find the treatment unsuitable or difficult to tolerate.
- Gallbladder disease or gallstones: Rapid weight loss and the use of GLP-1 medications can increase the likelihood of gallbladder issues, so anyone with active gallbladder disease may need additional medical assessment before treatment is approved.
- Pregnancy, breastfeeding, or trying to conceive: Neither Wegovy nor Mounjaro are considered safe during pregnancy or while breastfeeding. Patients are usually advised to stop treatment well before trying for a baby due to how weight-loss medications “may affect foetal development.”
- Other existing medical conditions: From severe liver disease, to kidney problems, to poorly managed diabetes, various conditions could render the medications unsuitable.
- History of eating disorders: Patients with current or previous eating disorders are unlikely to be approved for treatment. Appetite-suppressing medications have the potential to worsen disordered eating behaviours or negatively impact mental wellbeing.
- Uncontrolled mental health conditions: Severe or unmanaged mental health conditions may need to be stabilised before treatment can begin.
- Severe side effects during previous use: If someone has previously taken a GLP-1 medication and experienced severe vomiting, dehydration, or ongoing digestive side effects, clinicians may decide it is not appropriate to restart treatment.
- Medication interactions or allergies: Certain medications can interact poorly with weight loss injections, and some people may be allergic to ingredients used within them.
- Drug or alcohol misuse concerns: Where there are worries about the safe management of prescription medication in regards to substance abuse, patients may need extra support or assessment before treatment can go ahead.
- Age restrictions: While Wegovy is approved for weight loss in patients aged 12 and over, Mounjaro can only be prescribed to over-18s.
- Unsafe prescribing concerns: Patients may be declined a prescription if the information they provided is incomplete, inconsistent, or suggests the medication may not be being used appropriately.
Conclusion
It is relatively common for people to be declined treatment, and in many cases, refusal is about protecting a patient’s long-term health and ensuring that the risks of treatment do not outweigh the benefits. Doctors must follow strict medical guidance around who can safely receive treatment. Weight-loss injections are powerful prescription medications that are not suitable for everyone.
